Person—glycosylated haemoglobin level (measured), percentage N[N].N
Data Element Attributes
Identifying and definitional attributes | |
Metadata item type:![]() | Data Element |
---|---|
Short name:![]() | Glycosylated haemoglobin level (measured) |
METEOR identifier:![]() | 270325 |
Registration status:![]() |
|
Definition:![]() | A person's glycosylated haemoglobin (HbA1c) level, measured as percentage. |
Data Element Concept:![]() | Person—glycosylated haemoglobin level |
Value domain attributes | |||||
Representational attributes | |||||
Representation class:![]() | Percentage | ||||
---|---|---|---|---|---|
Data type:![]() | Number | ||||
Format:![]() | N[N].N | ||||
Maximum character length:![]() | 3 | ||||
Supplementary values:![]() |
| ||||
Data element attributes | |||||
Collection and usage attributes | |||||
Guide for use:![]() | HbA1c results vary between laboratories; use the same laboratory for repeated testing. When reporting, record absolute result of the most recent HbA1c level in the last 12 months. Record the absolute result of the test (%). | ||||
Collection methods:![]() | Test is performed in accredited laboratories:
| ||||
Source and reference attributes | |||||
Submitting organisation:![]() | National diabetes data working group | ||||
Origin:![]() | National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. | ||||
Reference documents:![]() | Koening, R. J. Peterson, CM and Kilo, C et al. Hemoglobin A1c as an indicator of the degree of glucose intolerance in diabetes. Diabetes 259 (1976): 230-232. Nathan, D.M., Singer, D.E, Hurxthal, K, and Goodson, J.D. The clinical information value of the glycosylated hemoglobin assay. N. Eng. J. Med. 310 (1984): 341-346. | ||||
Relational attributes | |||||
Related metadata references:![]() | Is re-engineered from ![]() See also Laboratory standard—upper limit of normal range of glycosylated haemoglobin, percentage N[N].N
| ||||
Implementation in Data Set Specifications:![]() | Health, Superseded 01/09/2012 Health, Superseded 02/05/2013 Health, Standard 02/05/2013 Implementation start date: 01/07/2013 Health, Superseded 21/09/2005 Health, Standard 21/09/2005 DSS specific information: The HbA1c along with regular blood glucose monitoring is the best way to see the overall picture of blood glucose levels. HbA1c is a measurement of long-term blood glucose control and is used to assess the effectiveness of treatment. The level of HbA1c is proportional to the level of glucose in the blood over a period of approximately two months, because glucose attaches to the haemoglobin (red blood cells) and remains there for the life of the red blood cell, approximately 120 days. The HbA1c gives an average of the blood glucose level over the past 6-8 weeks and therefore HbA1c is accepted as an indicator of the mean daily blood glucose concentration over the preceding two months. HbA1c is formed by the non-enzymatic glycation of the N-terminus of the B- chain of haemoglobin Ao. It is a convenient way to obtain an integrated assessment of antecedent glycaemia over an extended period under real life conditions used as a standard for assessing overall blood glucose control. Research studies in the United States have found that for every 1% reduction in results of HbA1c blood tests, the risk of developing micro vascular diabetic complications (eye, kidney, and nerve disease) is reduced by 40 percent. The maintenance of good glycaemic control (in diabetes Type 1 and Type 2), significantly reduces progression of diabetes-related complications such as retinopathy, nephropathy and neuropathy, as indicated in the Diabetes Control and Complications Trial (DCCT 1993) and United Kingdom Prospective Diabetes Study (UKPDS 1997). The target proposed by the Australian Diabetes Society for glycosylated haemoglobin (HbA1c)is 7.0% or less and a doctor may order this test about every 3 - 6 months. |